Business Context and Reporting Period
Company: BioRestorative Therapies, Inc. (BRTX)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2026
Business Overview: BRTX develops therapeutic products using adult stem cells, focusing on the BRTX-100 candidate for lumbar disc disorders and the ThermoStem Program for metabolic disorders. The company also operates a biocosmeceutical division selling ExoCR and BioX products.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenues | $23,170 | $25,000 |
| Net Loss | $(2,154,405) | $(5,339,799) |
| Net Loss Per Share (Basic & Diluted) | $(0.12) | $(0.64) |
| Cash and Cash Equivalents | $3,112,679 | $1,228,789 |
| Working Capital | $2,185,071 | $(586,029) |
| Operating Cash Flow | $(3,807,792) | $(2,778,786) |
| Financing Cash Flow | $4,440,836 | $1,092,718 |
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased by approximately $3.2 million (60%) compared to Q1 2025. This improvement was primarily driven by a $1.22 million gain from the change in fair value of warrant liabilities and a significant reduction in stock-based compensation expenses.
- Revenue Composition: Total revenue remained flat but shifted in composition. Royalty revenue decreased by 55% to $11,300 due to fewer disc procedures. Product revenue increased to $11,870, driven by the commencement of commercial sales of the BioX product line.
- Expense Reduction: Operating expenses decreased by $1.4 million. Research and Development (R&D) expenses fell by 27% and General and Administrative (G&A) expenses fell by 32%, largely due to lower stock-based compensation.
- Liquidity Improvement: Working capital turned positive ($2.2 million) from a deficiency of $0.6 million in the prior year-end. This was driven by a $5.0 million public offering (Rodman Offering) and the reclassification of warrant liabilities to equity.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern Warning: Management states that current funds are insufficient to complete development activities or attain profitability. The company anticipates continued net losses and negative operating cash flows, raising substantial doubt about its ability to continue as a going concern for at least twelve months without additional financing.
- Nasdaq Compliance: The company received notice of non-compliance with Nasdaq's minimum bid price requirement ($1.00 per share) on March 26, 2026. It has a 180-day compliance period ending September 22, 2026, to regain compliance, potentially via a reverse stock split.
- Unusual Items:
- Warrant Reclassification: On February 24, 2026, following the conversion of Series B Preferred Stock, warrants previously classified as liabilities were reclassified to equity. This resulted in a one-time gain of $1,220,121.
- Voluntary Revision: The company voluntarily revised Q1 2025 financial statements to reclassify $932,573 of stock-based compensation from G&A to R&D.
- Internal Controls: The company identified material weaknesses in internal controls over financial reporting, including a lack of formal policies and risk assessment procedures. Management is implementing a remediation plan.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $3.1 million cash balance against projected burn rates for clinical trials (BRTX-100 Phase 2) and operations.
- Nasdaq Status: Monitor the stock price to ensure compliance with the $1.00 minimum bid price requirement by September 22, 2026, to avoid delisting.
- Revenue Sustainability: Assess the scalability of the new BioX product revenue ($11,870 in Q1) and the volatility of royalty revenue dependent on third-party procedures.
- Internal Controls: Review progress on remediation of material weaknesses in financial reporting to ensure future financial statement reliability.
- Dilution Risk: Note the significant increase in outstanding shares (from ~8.9M to ~25.5M) due to the recent offering and warrant exercises, which may impact future per-share value.